Spatial transcriptomics reveals key differences in Alport disease progression and potential targets of hEV treatment in Alport disease

Alport syndrome is a glomerular disease. To understand the disease progression of alport syndrome and potential therapeutical effects of hEV derived from AFSCs, we performed spatial transcriptomics to profile the heterogeniety of cell populations in kidneys of mouse of AS through disease progression and hEV treated AS mice as well. Our analysis sheds light on key functional parts of the kidney responsible in disease progression as well as potential targets of hEV therapy. WT, Early and late stage alport syndrome mouse models were used to profile the spatial transcriptomics of the disease progression. Early treated 5m AS and Late treated 5m AS were used to profile the spatial trascriptomics of the hEV treated AS